ScholarLens Back to search
2006•Xinxueguan kangfu yixue zazhiRequires access

Compare effects of intravenous amiodarone and cedilanid in the treatment of paroxysmal atrial fibrillation

Ren Xu-gong

Open publisher page 0 citations

Abstract

Objective:To compare the acute efficacy and safety of intravenous amiodarone and cedilanid in the treatment of paroxysmal atrial fibrillation (PAF). Methods: The 84 PAF patients which PAF duration was 24-72 h were average divided into amiodarone group and cedilanid group. Amiodarone 150-1180 mg and cedilanid 0. 4-0. 8 mg were given intravenously respectively. Results:The rate of conversion to sinus rhythm was 83. 3% by amiodarone group and 42. 9% by cedilanid group; its difference was significant (P0. 01). The ventricular rate in no reverted patients were decreased from (128. 4±12. 3) to (87. 8±11.4) times/min by amiodarone (P0. 01) and from (129.6±13. 1) to (90. 3±11. 9) times/min (P0. 01) by cedilanid. No sever side effects were found in two groups. Conclusion: Intravenous amiodarone is effective and safe in the treatment of paroxysmal atrial fibrillation; its reverted rate is significantly higher than cedilanid.

About this research paper

What this paper is about

Objective:To compare the acute efficacy and safety of intravenous amiodarone and cedilanid in the treatment of paroxysmal atrial fibrillation (PAF). Methods: The 84 PAF patients which PAF duration was 24-72 h were average divided into amiodarone group and cedilanid group. Amiodarone 150-1180 mg and cedilanid 0. 4-0. 8 mg were given intravenously respectively. Results:The rate of conversion to sinus rhythm was 83. 3% by amiodarone group and 42. 9% by cedilanid group; its difference was significant (P0. 01). The ventricular rate in no reverted patients were decreased from (128. 4±12. 3) to (87. 8±11.4) times/min by amiodarone (P0. 01) and from (129.6±13. 1) to (90. 3±11. 9) times/min (P0. 01) by cedilanid. No sever side effects were found in two groups. Conclusion: Intravenous amiodarone is effective and safe in the treatment of paroxysmal atrial fibrillation; its reverted rate is significantly higher than cedilanid.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To compare the acute efficacy and safety of intravenous amiodarone and cedilanid in the treatment of paroxysmal atrial fibrillation (PAF). Methods: The 84 PAF patients which PAF duration was 24-72 h were average divided into amiodarone group and cedilanid group. Amiodarone 150-1180 mg and cedilanid 0. 4-0. 8 mg were given intravenously respectively. Results:The rate of conversion to sinus rhythm was 83. 3% by amiodarone group and 42. 9% by cedilanid group; its difference was significant (P0. 01). The ventricular rate in no reverted patients were decreased from (128. 4±12. 3) to (87. 8±11.4) times/min by amiodarone (P0. 01) and from (129.6±13. 1) to (90. 3±11. 9) times/min (P0. 01) by cedilanid. No sever side effects were found in two groups. Conclusion: Intravenous amiodarone is effective and safe in the treatment of paroxysmal atrial fibrillation; its reverted rate is significantly higher than cedilanid.

Key concepts: Amiodarone, Medicine, Atrial fibrillation, Sinus rhythm, Ventricular rate, Paroxysmal atrial fibrillation, Cardiology, Anesthesia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Compare effects of intravenous amiodarone and cedilanid in the treatment of paroxysmal atrial fibrillation — Research Paper | ScholarLens